-
Innovation Ranking
NewInnovation Ranking – TG Therapeutics Inc
TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases. The company’s approved products in the US include Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. The pipeline products of the company include TG-1701 and TG-1801 for the treatment of B-cell cancers and other diseases. The company also evaluates products and technologies for in-licensing, partnership,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Cancer Drug Details: TG-01 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Ductal Adenocarcinoma Drug Details: TG-01 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TG-1042 in Cutaneous B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-1042 in Cutaneous B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-1042 in Cutaneous B-Cell Lymphoma Drug Details: TG-1042 (ASN-002) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Non-Small Cell Lung Cancer Drug Details: TG-01...
-
Product Insights
NewLikelihood of Approval Analysis for Heterozygous familial hypercholesterolemia (heFH)
Overview How likely is it that the drugs in Heterozygous familial hypercholesterolemia (heFH) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Heterozygous familial hypercholesterolemia (heFH) Overview Heterozygous familial hypercholesterolemia (HeFH) is...
-
Company Insights
Innovation and Patenting activity of TGS ASA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TGS ASA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Head And Neck Squamous Cell...
-
Company Insights
Innovation and Patenting activity of TG Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TG Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Hypertriglyceridemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Hypertriglyceridemia Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...